Personalized breast cancer screening guided by tumor biology
Project 1: Implementing Risk-based Tools that Incorporate Tumor Biology to Optimize Screening and Prevention
This project uses tumor biology and individual risk to give women personalized breast cancer screening and prevention plans.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11191508 on NIH RePORTER |
What this research studies
If you join, the team will use models that predict whether you're more likely to develop fast‑growing or slow‑growing breast cancers and tailor screening and prevention accordingly. Women at higher risk for fast‑growing cancers may be offered earlier and more frequent screening with more sensitive imaging, while those at higher risk for slow‑growing cancers may be offered endocrine risk‑reducing therapy. The project extends the WISDOM program by determining the tumor subtype for cancers that arose in the original WISDOM group and in newly enrolled participants to compare outcomes. Data will come from imaging, biopsies, and medical records collected across participating centers.
Who could benefit from this research
Good fit: Women who are eligible for routine breast cancer screening and willing to share medical records, imaging, and possibly tissue samples are the ideal candidates.
Not a fit: People who are outside routine screening age, already have a breast cancer diagnosis, or are unwilling to provide medical or imaging data may not receive benefit from this project.
Why it matters
Potential benefit: If successful, this could help catch aggressive cancers earlier while reducing unnecessary tests and treatments for others.
How similar studies have performed: The original WISDOM trial and other risk-based screening efforts have shown promise for personalized screening, but using subtype-specific tumor biology to guide screening is a newer approach that remains to be proven.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Esserman, Laura J — University of California, San Francisco
- Study coordinator: Esserman, Laura J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.